NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a deal to distribute its SelectMDx for Prostate Cancer test in various countries in Central and South America.
Under the terms of the agreement, Uruguay-based biotechnology company SouthGenetics will have the rights to distribute SelectMDx in Argentina, Bolivia, Chile, Columbia, Ecuador, Mexico, Peru, the Dominican Republic, Panama, Paraguay, Uruguay, and Venezuela.
Further terms of the deal were not disclosed.
"MDxHealth is pleased to have this opportunity to provide SelectMDx testing for patients throughout Latin America through this collaborative agreement with SouthGenetics, helping to improve both the quality of care and outcomes for those suspected of harboring prostate cancer throughout Latin America," MDxHealth CEO Jan Groen said in a statement.
MDxHealth recently announced that it has also signed a distribution agreement with The European Health Centre Innovation for both the SelectMDx and ConfirmMDx for Prostate Cancer tests in Poland.